New Guidelines Warn Against Calcium Channel Blockers in Certain Patients

Published Online: Friday, October 1, 2004

Recent guidelines from the New American College of Chest Physicians alert practitioners to the potentially fatal effects of prescribing calcium channel blockers for patients with unstable pulmonary arterial hypertension (PAH). While those drugs are commonly used for treating high blood pressure, these new, evidence-based guidelines warn against empiric use in patients unresponsive to acute pulmonary vasodilator testing due to an increased risk of adverse and possibly fatal side effects. Members of the expert panel who determined these new guidelines recommend that physicians conduct genetic testing on patients who have a family history of PAH, as well as advance screening for patients with chronic diseases that may predispose them to PAH. (The findings were reported in Chest, July 2004.)

Latest Articles
Donnie Calhoun, RPh, PD, National Community Pharmacists Association (NCPA) Foundation vice president, discusses how pharmacists can prepare themselves and their business before, during, and after a disaster.
Ken Whittemore Jr, Surescript's senior vice president of professional and regulatory affairs, talks about some new transactions available that can help pharmacists.
In case you got caught up in the Thanksgiving holiday rush, here are the top trending stories you may have missed in November:
Bryan Ziegler, PharmD, executive director of Kennedy Pharmacy Innovation Center, provides some resources for community pharmacists to use when implementing new collaborative services with primary care providers.
Latest Issues